Alphabody

Last updated

Alphabodies, also known as Cell-Penetrating Alphabodies or CPAB for short, are small 10 kDa proteins engineered to bind to a variety of antigens. Despite their name, they are not structurally similar to antibodies, which makes them a type of antibody mimetic. Alphabodies are different from many other antibody mimetics in their ability to reach and bind to intracellular protein targets. [1] Their single chain alpha-helical structure is designed by computer modelling, inspired by naturally existing coiled-coil protein structures. Alphabodies are being developed by the Belgian biotechnology company Complix N.V. as potential new pharmaceutical drugs against cancer and autoimmune disease. [2] In 2012, a collaboration agreement was signed with Monsanto to develop the technology for agricultural applications as well. [3]

Contents

3D structure of the alphabody scaffold, showing a single chain, triple-helix coiled-coil fold. (PDB 4OG9) Alphabody1.png
3D structure of the alphabody scaffold, showing a single chain, triple-helix coiled-coil fold. (PDB 4OG9)

Development

Alphabodies are developed as scaffolds with a set of amino acid residues that can be modified to bind protein targets, while maintaining correct folding and thermostability.

The Alphabody scaffold is computationally designed based on coiled-coil structures, but it has no known counterpart in nature. Initially, the scaffold was made of three peptides that associated non-covalently to form a parallel coiled-coil trimer. [4] However, the scaffold was later redesigned as a single peptide chain containing three α-helices connected by linker regions. The new structure allows for concentration-independent assembly and cost-effective scaling in bacterial expression systems. [1]

The three α-helices (A, B, and C) were designed to remain stable even when some residues are modified. Residues in the groove between helices A and C can be modified to bind convex targets, while residues on the outside of helix C can be modified to bind concave protein targets. There are currently 3 libraries containing 1.0 to 1.7 × 108 variations each that can be screened using phage display for target affinity.

Structure

Alphabody denaturation data comparing truncated Alphabody stability to reference scaffold AlphabodyDN.jpg
Alphabody denaturation data comparing truncated Alphabody stability to reference scaffold

Standard

The standard Alphabody scaffold contains three α-helices, composed of four heptad repeats (stretches of 7 residues) each, connected via glycine/serine-rich linkers. The standard heptad sequence is "IAAIQKQ". Alanines are associated with α-helix formation, while isoleucines are known to induce coiled-coil formation. [5] Specific residues on the A and C helices can be modified to bind targets, but only variants that retain thermostability are used for further research.

Specifically, the reference scaffold structure is N–HRS1–L1–HRS2–L2–HRS3–C.

HRS = IEEIQKQIAAIQKQIAAIQKQIYRM; L = TGGSGGGSGGGSGGGSGMS

The linker length is long enough to allow helices to fold in parallel or anti-parallel conformations, but experiments suggest only anti-parallel folding occurs. [1]

Truncated version

An Alphabody scaffold variant with shorter linkers can be produced without the loss of thermostability. However, decreasing the number of heptad repeats per α-helix reduces the thermostability of the Alphabody by around 40 °C.

Properties

Alphabody denaturation data from circular dichroism experiments AlphabodyCD.jpg
Alphabody denaturation data from circular dichroism experiments

Alphabodies have low molecular weight (~10 kDa) and very high thermostability (Tm = ~120 °C). Moreover, circular dichroism experiments suggest that Alphabodies can refold correctly after being denatured. These properties allow Alphabody-based drugs to be administered in ways other than injection. [6] They also make the molecule stable enough to allow modification of residues on the scaffold itself – rather than only loop regions – increasing the possible variations and target selectivity. [1]

Alphabodies' high binding affinity and ability to target both extracellular and intracellular proteins allows them to be used to reach difficult targets that cannot be treated by therapeutic antibodies or small molecule drugs.

Targets

3D structure of Alphabody in complex with IL-23 p19 subunit AlphabodyXRC.jpg
3D structure of Alphabody in complex with IL-23 p19 subunit

Autoimmune disease

Alphabody CMPX-1023 has been successfully developed to target the p19 subunit of Interleukin 23 (IL-23) and has entered preclinical trials as of October 2011. [6] [7] In brief, IL-23 is a pro-inflammatory cytokine that has been implicated in autoimmune inflammatory diseases like psoriasis, rheumatoid arthritis and Crohn's disease. [8] There are anti-IL-23 drugs available, which work by targeting the p40 subunit. However, the p40 subunit is also present in Interleukin 12 (IL-12) and causes serious side-effects when antagonized, such as increased susceptibility to infection.

Complix N.V. used phage display to create Alphabodies that could bind IL-23, and then employed several affinity maturation strategies to increase affinity to sub-nanomolar levels. They determined increased affinity resulted in increased functional inhibition of IL-23 and thus selected top 20 strongest binding Alphabodies as drug candidates. Mouse studies and X-ray crystallography studies on IL-23 in complex with the Alphabody confirmed specific binding to p19 only.

Cancer

Using a similar drug development strategy, Complix N.V. is developing Alphabodies capable of binding intracellular targets in cancer cells that can induce apoptosis. According to a 2012 article, Complix has had a degree of success in doing so:

"These results show that Alphabodies can be designed to efficiently enter human cells and bind to targets of interest, allowing them to modulate intracellular protein-to-protein interactions and induce apoptosis in cancer cells. Complix expects to report further break-through data from this important program over the course of 2012." [9]

Funding

The research on IL-23-specific Alphabodies was supported by grants from IWT-O&O, Ghent University, and the Hercules foundation (Belgium).

Complix N.V. is funded by equity shareholders Baekeland Fund, Biotech Fund Flanders, CRP-Santé, Edmond de Rothschild Investment Partners, Gemma Frisius Fund, Gimv, LRM, OMNES Capital, TrustCapital, Vesalius Biocapital, and Vinnof. [10]

See also

Related Research Articles

Alpha helix type of secondary structure

The alpha helix (α-helix) is a common motif in the secondary structure of proteins and is a right hand-helix conformation in which every backbone N−H group hydrogen bonds to the backbone C=O group of the amino acid located three or four residues earlier along the protein sequence.

G protein-coupled receptor large protein family of receptors that detect molecules outside the cell and activate internal signal transduction pathways and cellular responses

G protein-coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptor, and G protein-linked receptors (GPLR), constitute a large protein family of receptors that detect molecules outside the cell and activate internal signal transduction pathways and, ultimately, cellular responses. Coupling with G proteins, they are called seven-transmembrane receptors because they pass through the cell membrane seven times.

Receptor (biochemistry) protein molecule receiving signals for a cell

In biochemistry and pharmacology, receptors are chemical structures, composed of protein, that receive and transduce signals that may be integrated into biological systems. These signals are typically chemical messengers, which bind to a receptor, they cause some form of cellular/tissue response, e.g. a change in the electrical activity of a cell. There are three main ways the action of the receptor can be classified: relay of signal, amplification, or integration. Relaying sends the signal onward, amplification increases the effect of a single ligand, and integration allows the signal to be incorporated into another biochemical pathway. In this sense, a receptor is a protein-molecule that recognizes and responds to endogenous chemical signals. For example, an acetylcholine receptor recognizes and responds to its endogenous ligand, acetylcholine. However, sometimes in pharmacology, the term is also used to include other proteins that are drug targets, such as enzymes, transporters, and ion channels.

A coiled coil is a structural motif in proteins in which 2–7 alpha-helices are coiled together like the strands of a rope. Many coiled coil-type proteins are involved in important biological functions such as the regulation of gene expression, e.g. transcription factors. Notable examples are the oncoproteins c-Fos and c-jun, as well as the muscle protein tropomyosin.

Affinity chromatography is a method of separating biochemical mixture based on a highly specific interaction between antigen and antibody, enzyme and substrate, receptor and ligand, or protein and nucleic acid. It is a type of chromatographic laboratory technique used for purifying biological molecules within a mixture by exploiting molecular properties, e.g. protein can be eluted by ligand solution. Biological macromolecules, such as enzymes and other proteins, interact with other molecules with high specificity through several different types of bonds and interaction. Such interactions include hydrogen bonding, ionic interaction, disulfide bridges, hydrophobic interaction, and more. The high selectivity of affinity chromatography is caused by allowing the desired molecule to interact with the stationary phase and be bound within the column in order to be separated from the undesired material which will not interact and elute first. The molecules no longer needed are first washed away with a buffer while the desired proteins are let go in the presence of the eluting solvent. This process creates a competitive interaction between the desired protein and the immobilized stationary molecules, which eventually lets the now highly purified proteins be released.

Aptamer oligonucleic acid or peptide molecule that binds to a specific target molecule

Aptamers are oligonucleotide or peptide molecules that bind to a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist in riboswitches. Aptamers can be used for both basic research and clinical purposes as macromolecular drugs. Aptamers can be combined with ribozymes to self-cleave in the presence of their target molecule. These compound molecules have additional research, industrial and clinical applications.

T-cell receptor Protein complex on the surface of T cells that recognises antigens

The T-cell receptor (TCR) is a protein complex found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate: that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.

Protein tags are peptide sequences genetically grafted onto a recombinant protein. Often these tags are removable by chemical agents or by enzymatic means, such as proteolysis or intein splicing. Tags are attached to proteins for various purposes.

Leucine zipper DNA-binding structural motif

A leucine zipper is a common three-dimensional structural motif in proteins. They were first described by Landschulz and collaborators in 1988 when they found that an enhancer binding protein had a very characteristic 30-amino acid segment and the display of these amino acid sequences on an idealized alpha helix revealed a periodic repetition of leucine residues at every seventh position over a distance covering eight helical turns. The polypeptide segments containing these periodic arrays of leucine residues were proposed to exist in an alpha-helical conformation and the leucine side chains from one alpha helix interdigitate with those from the alpha helix of a second polypeptide, facilitating dimerization.

Myristoylation protein modification

Myristoylation is a lipidation modification where a myristoyl group, derived from myristic acid, is covalently attached by an amide bond to the alpha-amino group of an N-terminal glycine residue. Myristic acid is a 14-carbon saturated fatty acid (14:0) with the systematic name of n-Tetradecanoic acid. This modification can be added either co-translationally or post-translationally. N-myristoyltransferase (NMT) catalyzes the myristic acid addition reaction in the cytoplasm of cells. This lipidation event is the most found type of fatty acylation and is common among many organisms including animals, plants, fungi, protozoans and viruses. Myristoylation allows for weak protein–protein and protein–lipid interactions and plays an essential role in membrane targeting, protein–protein interactions and functions widely in a variety of signal transduction pathways.

Gp41

Gp41 also known as glycoprotein 41 is a subunit of the envelope protein complex of retroviruses, including human immunodeficiency virus (HIV). Gp41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. As a result of its importance in host cell infection, it has also received much attention as a potential target for HIV vaccines.

Beta helix protein structure

A beta helix is a tandem protein repeat structure formed by the association of parallel beta strands in a helical pattern with either two or three faces. The beta helix is a type of solenoid protein domain. The structure is stabilized by inter-strand hydrogen bonds, protein-protein interactions, and sometimes bound metal ions. Both left- and right-handed beta helices have been identified. Double stranded beta-helices are also very common features of proteins and are generally synonymous with jelly roll folds.

Enzyme inhibitor molecule that binds to an enzyme and decreases its activity

An enzyme inhibitor is a molecule that binds to an enzyme and decreases its activity. By binding to enzymes' active sites, inhibitors reduce the compatibility of substrate and enzyme and this leads to the inhibition of Enzyme-Substrate complexes' formation, preventing the catalyzation of reactions and decreasing the amount of product produced by a reaction. It can be said that as the concentration of enzyme inhibitors increases, the rate of enzyme activity decreases, and thus, the amount of product produced is inversely proportional to the concentration of inhibitor molecules. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. They are also used in pesticides. Not all molecules that bind to enzymes are inhibitors; enzyme activators bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.

Affibody molecules are small, robust proteins engineered to bind to a large number of target proteins or peptides with high affinity, imitating monoclonal antibodies, and are therefore a member of the family of antibody mimetics. Affibody molecules are used in biochemical research and are being developed as potential new biopharmaceutical drugs. These molecules can be used for molecular recognition in diagnostic and therapeutic applications.

Antibody mimetics are organic compounds that, like antibodies, can specifically bind antigens, but that are not structurally related to antibodies. They are usually artificial peptides or proteins with a molar mass of about 3 to 20 kDa.

Affilin

Affilins are artificial proteins designed to selectively bind antigens. Affilin proteins are structurally derived from human ubiquitin. Affilin proteins are constructed by modification of surface-exposed amino acids of these proteins and isolated by display techniques such as phage display and screening. They resemble antibodies in their affinity and specificity to antigens but not in structure, which makes them a type of antibody mimetic. Affilin was developed by Scil Proteins GmbH as potential new biopharmaceutical drugs, diagnostics and affinity ligands.

Nest (protein structural motif) Protein structural motif

The Nest is a type of protein structural motif. It is a small recurring anion-binding feature of both proteins and peptides. Each consists of the main chain atoms of three consecutive amino acid residues. The main chain NH groups bind the anions while the side chain atoms are often not involved. Proline residues lack NH groups so are rare in nests. About one in 12 of amino acid residues in proteins, on average, belongs to a nest.

Synthetic antibodies are affinity reagents generated entirely in vitro, thus completely eliminating animals from the production process. Synthetic antibodies include recombinant antibodies, nucleic acid aptamers and non-immunoglobulin protein scaffolds. As a consequence of their in vitro manufacturing method the antigen recognition site of synthetic antibodies can be engineered to any desired target and may extend beyond the typical immune repertoire offered by natural antibodies. Synthetic antibodies are being developed for use in research, diagnostic and therapeutic applications. Synthetic antibodies can be used in all applications where traditional monoclonal or polyclonal antibodies are used and offer many inherent advantages over animal-derived antibodies, including comparatively low production costs, reagent reproducibility and increased affinity, specificity and stability across a range of experimental conditions.

Affimer

Affimer molecules are small proteins that bind to target molecules with similar specificity and affinity to that of antibodies. These engineered non-antibody binding proteins are designed to mimic the molecular recognition characteristics of monoclonal antibodies in different applications. In addition, these affinity reagents have been optimized to increase their stability, make them tolerant to a range of temperatures and pH, reduce their size, and to increase their expression in E.coli and mammalian cells.

References

  1. 1 2 3 4 Desmet, J.; Verstraete, K.; Bloch, Y.; Lorent, E.; Wen, Y.; Devreese, B.; Vandenbroucke, K.; Loverix, S.; Hettmann, T.; Deroo, S.; Somers, K.; Henderikx, P.; Lasters, I.; Savvides, S. N. (5 Feb 2014). "Structural basis of IL-23 antagonism by an Alphabody protein scaffold". Nature Communications. 5: 5237. doi:10.1038/ncomms6237. PMC   4220489 . PMID   25354530.
  2. "Complix - About Complix". Complix. Archived from the original on 14 February 2015. Retrieved 9 March 2015.
  3. Powers, K. "Monsanto Company and Complix Nv Sign Collaboration to Bring New Technologies to Agriculture". Monsanto. Archived from the original on 2 April 2015. Retrieved 26 March 2015.
  4. Desmet, J.; Lasters, I. (2010). "Non-natural proteinaceous scaffold made of three non-covalently associated peptides". US Patents (US20100305304 A1).
  5. Suzuki, K.; Hiroaki, H.; Kohda, D.; Tanaka, T. (1998). "An isoleucine zipper peptide forms a native-like triple stranded coiled coil in solution". Protein Engineering. 11 (11): 1051–1055. doi: 10.1093/protein/11.11.1051 .
  6. 1 2 "Complix selects first Alphabody™ development candidate". FlandersBio. 25 October 2011. Retrieved 26 March 2015.
  7. "CMPX-1023". BioCentury BCIQ. Retrieved 26 March 2015.
  8. Benson, J.M.; Sachs, C.; Treacy, G.; Zhou, H.; Pendley, C.E.; Brodmerkel, C.M.; Shankar, G.; Mascelli, M.A. (2011). "Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab". Nat. Biotechnol. 29 (7): 615–624. doi:10.1038/nbt.1903. PMID   21747388.
  9. "Complix' Alphabody™ Protein Therapeutics Demonstrate Activity against both Undruggable Extracellular and Intracellular Disease Targets". PR Newswire. April 26, 2012. Retrieved 26 March 2015.
  10. "Complix NV Raises $15.5 Million in Series B Round". ClinicaSpace. 26 June 2013. Retrieved 26 March 2015.